CL401 VacciGrade™

Dual TLR2 & TLR7 agonist

CL401 is a chimeric molecule that co-activates the surface receptor TLR2 and the endosomal receptor TLR7. It is composed of 8-hydroxyadenine (TLR7 ligand) conjugated to Pam2C (TLR2 ligand). This chimeric compound displays strong adjuvant activity. In mice, administration of OVA with CL401 leads to a significant increase of anti-OVA IgG titers in sera. The predominant IgG subclass is IgG1, a Th2-associated isotype. The IgG2a subclass, a Th1-associated isotype, is also significantly increased resulting in a decreased IgG1/IgG2a ratio.

CL401 VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.

CL401 VacciGrade™ is for research use only, not for use in humans.


Description: TLR2 & TLR7 VacciGrade Agonist
Synonym: S-(2,3-bis(palmitoyloxy)-(2RS)propyl)-(R)-cysteinyl4-((6-amino-2(butyl amino)-8-hydroxy-9H-purin-9-yl)methyl)aniline
Formula: C54H92N8O4S
Molecular weight: 981
Solubility: 20 mg/ml in DMSO
Quality: Sterile
Endotoxin Level: Lower than 5 EU/mg
Working concentration: 20 - 50 µg/mouse


- 5 mg CL401 VacciGrade™ 
- 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)


CL401 chemical structure



InvivoGen has developed a series of novel molecules designed to induce potent immune responses through the combined activation of several pattern recognition receptors (PRRs) that trigger different innate immune signaling pathways. These molecules are agonists for TLR2, TLR7 or both. Agonists that activate TLR2 are derived from the well-established TLR2 ligand, Pam2CSK4, and those recognized by TLR7 are derived from the 8-hydroxyadenine derivative CL264, a TLR7 agonist recently developed by InvivoGen.

TLR2 and TLR7 are two PRRs with distinct characteristics. TLR2 is a cell surface receptor expressed by many cell types, while TLR7 is an endosomal receptor expressed predominantly in plasmacytoid dendritic cells (pDC) and to a lesser extent in B cells. TLR2 signaling triggers the NF-kB pathway and the production of pro-inflammatory cytokines, such as TNF-α, whereas TLR7 signaling induces mainly the IRF pathway and the production of IFN-α.


CL401 VacciGrade™

Description TLR2 & TLR7-based adjuvant
Cat. Codevac-c401-5
Unit Size5 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".